All Updates

All Updates

icon
Filter
Funding
Larkspur Bioscience raises USD 35.5 million in seed and Series A funding; launches from stealth
Precision Medicine
May 23, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

May 23, 2023

Larkspur Bioscience raises USD 35.5 million in seed and Series A funding; launches from stealth

Funding

  • Drug discovery and developer Larkspur Biosciences has launched out of stealth with USD 35.5 million in seed and Series A funding. The round was led by the Polaris Innovation Fund, 3E Bioventures Capital, and Takeda Ventures, Inc., and included other investors Creacion Ventures, Med-Fine Capital, and Cornell University.

  • The funds will be used for preclinical work on its lead program and will also support research on its secondary program.

  • Larkspur Biosciences is a preclinical biotechnology startup focused on developing precision immunotherapies, beginning with colorectal cancer (CRC) characterized by specific genetic and immunological features. Larkspur's approach is based on cancer cell biology and immunology, leveraging patient genetics and immune phenotypes through its proprietary platform, LarkX. The company has three programs in its pipeline focusing on CRC, with opportunities to expand to multiple cancers.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.